Broadcom
AVGO
Alibaba
BABA
NVIDIA
NVDA
Taiwan Semiconductor
TSM
Oracle
ORCL
US Stock MarketDetailed Quotes
JSPR Jasper Therapeutics
- 5.740
- +0.180+3.24%
Trading Feb 26 15:38 ET
86.11MMarket Cap-1.21P/E (TTM)
5.800High5.500Low215.34KVolume5.610Open5.560Pre Close1.22MTurnover2.18%Turnover RatioLossP/E (Static)15.00MShares31.01052wk High1.03P/B56.75MFloat Cap4.55052wk Low--Dividend TTM9.89MShs Float188.800Historical High--Div YieldTTM5.40%Amplitude3.862Historical Low5.687Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Jasper Therapeutics Stock Forum
Jasper's Briquilimab Takes Center Stage: 6 Key Data Presentations to Reveal Treatment Breakthrough at AAAAI 2025
Why is this so cheap if they rate it Strong Buy $62.78
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
Wednesday, 8th January at 7:00 am
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile
Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points
100% (N=3) Com...
No comment yet